Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

NCT07705243 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: Anti-PD1
DRUG: Anti-PD1 combined with Becotatug Vedotin

Sponsor

Sun Yat-sen University

Collaborators

[object Object]